Unveiling the latest insights into Androgen Receptors in Prostate Cancer
Suleiman Zakari1, Christogonus Chichebe Ekenwaneze1, Emmanuel Chimuebuka Amadi1, Abrar Abuhamdia2, Olubanke Olujoke Ogunlana1, Suleiman Zakari31Department of Biochemistry, College of Science and Technology, Covenant University, Ogun State, Nigeria; Covenant Applied Informatics and Communication - Africa Centre of Excellence (CApIC-ACE), Covenant University, Ogun State, Nigeria2Department of Medical Laboratory Science, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, Palestine
3Department of Biochemistry, College of Medicine, Federal University of Health Sciences Otukpo, Benue State, Nigeria
Prostate cancer (PCa) is a major cause of cancer-related mortality worldwide, with a rising incidence observed over the years. The androgen receptor (AR) signaling pathway plays a pivotal role in male development and maintaining masculine characteristics. Dysregulation of AR signaling in PCa can lead to disease progression and resistance to standard therapies. Understanding the intricate regulation and function of AR in both healthy and diseased states is crucial for developing effective treatment strategies. This review comprehensively explores the role of androgen receptors in PCa susceptibility, disease progression, and treatment response by analyzing recent literature. An extensive search of peer-reviewed publications in major databases, including PubMed, Scopus, and Web of Science, was conducted using specific keywords related to androgen receptor, prostate cancer, disease progression, and treatment resistance. Relevant conference abstracts and clinical trial reports were also included. The review presents an overview of the role of androgen receptors in PCa initiation, progression, and treatment resistance. It also highlights the role of SPOP as an emerging biomarker associated with AR signaling dysregulation and their potential utility for early detection and personalized treatment approaches. Additionally, recent advances in targeting the AR pathway for novel therapeutic strategies to improve patient outcomes and overcome treatment resistance in advanced PCa are discussed. The findings contribute to a comprehensive understanding of the AR signaling pathway in PCa and offer insights into its multifaceted role in disease development and treatment response. They may pave the way for innovative therapeutic interventions and precision medicine approaches based on specific AR signaling profiles, enhancing patient care and reducing the burden of this lethal disease.
Keywords: Androgen deprivation therapy, androgen receptor, AR-targeted therapies, disease progression, prostate cancer, therapeutic resistanceManuscript Language: English